NLRP3 and early-onset autosomal dominant Alzheimer disease: The inhibitory effect of gallic acid on NLRP3 inflammasome activation makes gallic acid an attractive new candidate for the treatment of NLRP3-associated diseases, such as diabetes, gout, and Alzheimer’s disease.